JP2021521179A5 - - Google Patents
Info
- Publication number
- JP2021521179A5 JP2021521179A5 JP2020555504A JP2020555504A JP2021521179A5 JP 2021521179 A5 JP2021521179 A5 JP 2021521179A5 JP 2020555504 A JP2020555504 A JP 2020555504A JP 2020555504 A JP2020555504 A JP 2020555504A JP 2021521179 A5 JP2021521179 A5 JP 2021521179A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- substituted
- unsubstituted
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655723P | 2018-04-10 | 2018-04-10 | |
| US62/655,723 | 2018-04-10 | ||
| PCT/US2019/026646 WO2019199874A1 (en) | 2018-04-10 | 2019-04-09 | Morpholine derivates as inhibitors of vps34 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521179A JP2021521179A (ja) | 2021-08-26 |
| JPWO2019199874A5 JPWO2019199874A5 (https=) | 2022-04-13 |
| JP2021521179A5 true JP2021521179A5 (https=) | 2022-04-13 |
| JP7369140B2 JP7369140B2 (ja) | 2023-10-25 |
Family
ID=66248835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555504A Active JP7369140B2 (ja) | 2018-04-10 | 2019-04-09 | Ｖｐｓ３４の阻害剤としてのモルホリン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11236079B2 (https=) |
| EP (1) | EP3774792B1 (https=) |
| JP (1) | JP7369140B2 (https=) |
| KR (1) | KR102803763B1 (https=) |
| CN (1) | CN112533917B (https=) |
| AU (1) | AU2019251363B2 (https=) |
| CA (1) | CA3095512A1 (https=) |
| EA (1) | EA202092446A1 (https=) |
| ES (1) | ES2929292T3 (https=) |
| MX (1) | MX2020010577A (https=) |
| SG (1) | SG11202008851UA (https=) |
| WO (1) | WO2019199874A1 (https=) |
| ZA (1) | ZA202005899B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112533917B (zh) | 2018-04-10 | 2024-06-21 | 神经孔疗法股份有限公司 | 作为vps34的抑制剂的吗啉衍生物 |
| ES3032793T3 (en) | 2018-04-10 | 2025-07-24 | Neuropore Therapies Inc | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2008070740A1 (en) * | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| EP2475375A4 (en) * | 2009-09-09 | 2013-02-20 | Avila Therapeutics Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| ES2608967T3 (es) * | 2011-03-28 | 2017-04-17 | Mei Pharma, Inc. | (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas |
| DK3416957T3 (da) * | 2016-02-19 | 2020-09-21 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes |
| AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
| CN112533917B (zh) | 2018-04-10 | 2024-06-21 | 神经孔疗法股份有限公司 | 作为vps34的抑制剂的吗啉衍生物 |
-
2019
- 2019-04-09 CN CN201980032053.2A patent/CN112533917B/zh active Active
- 2019-04-09 AU AU2019251363A patent/AU2019251363B2/en active Active
- 2019-04-09 US US17/046,750 patent/US11236079B2/en active Active
- 2019-04-09 KR KR1020207032483A patent/KR102803763B1/ko active Active
- 2019-04-09 JP JP2020555504A patent/JP7369140B2/ja active Active
- 2019-04-09 ES ES19719103T patent/ES2929292T3/es active Active
- 2019-04-09 EA EA202092446A patent/EA202092446A1/ru unknown
- 2019-04-09 CA CA3095512A patent/CA3095512A1/en active Pending
- 2019-04-09 EP EP19719103.4A patent/EP3774792B1/en active Active
- 2019-04-09 WO PCT/US2019/026646 patent/WO2019199874A1/en not_active Ceased
- 2019-04-09 SG SG11202008851UA patent/SG11202008851UA/en unknown
- 2019-04-09 MX MX2020010577A patent/MX2020010577A/es unknown
-
2020
- 2020-09-23 ZA ZA2020/05899A patent/ZA202005899B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101678255B1 (ko) | 치환 아미드 화합물 | |
| TWI280876B (en) | Therapeutic drug for diabetes | |
| TWI323659B (en) | Novel thiazolidin-4-one derivatives | |
| RU2576036C2 (ru) | Модуляторы активности нес1 и способы для них | |
| AU2010301675B2 (en) | Novel phenol derivative | |
| JP2010510237A5 (https=) | ||
| EP2917190B1 (en) | New benzene sulfonamide thiazole compounds | |
| JP2017537940A5 (https=) | ||
| JP2018522866A5 (https=) | ||
| JPWO2023099623A5 (https=) | ||
| TW200524575A (en) | Biaryl linked hydroxamates: preparation and pharmaceutical applications | |
| KR20100112623A (ko) | 티아졸 유도체 및 ｖａｐ－１ 저해제로서 이의 용도 | |
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2020516616A5 (https=) | ||
| JP6867998B2 (ja) | ガンを処置するのに使用するための置換疎水性ベンゼンスルホンアミドチアゾール化合物 | |
| JP2021521179A5 (https=) | ||
| CZ304035B6 (cs) | N-fenylarylsulfonamidová sloucenina, farmaceutická kompozice obsahující tuto slouceninu jako úcinnou slozku, syntetický meziprodukt pro tuto slouceninu a zpusob jeho prípravy | |
| KR20080034436A (ko) | 암 치료에 사용되는 티아졸 유도체 및 유사체 | |
| JP2006516626A5 (https=) | ||
| CA2626402A1 (en) | Potassium channel inhibitors | |
| AU767151B2 (en) | Polycyclic thiazolidin-2-ylidene amines, method for the production and use thereof as medicaments | |
| IL144229A (en) | New history of N) –2– cyanoimino) thiazolidine – 4 – on | |
| AU2004291539A1 (en) | Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof | |
| WO2015102369A1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| KR20020002394A (ko) | 비만증 예방 또는 치료용 약제를 제조하기 위한,폴리사이클릭 2-아미노-티아졸계의 용도 |